All In Biotech

Drug Trial Radar · NCT03921541

Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency

PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints): A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Efficacy and Safety of Pegzilarginase in Children and Adults With Arginase 1 Deficiency

Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

32

Actual

Start

May 1, 2019

Primary completion

Feb 1, 2023

Study completion Feb 1, 2023

Sponsor

Lead sponsor
Immedica Pharma ABIndustry
Sponsor type
Industry
Collaborators
Aeglea Biotherapeutics
First posted
Apr 19, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

CAEB1102-300A is a multi-center randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of pegzilarginase in patients with ARG1-D. This study will consist of a screening period; a randomized, double-blind treatment period; a long-term extension; and a follow up visit for final safety assessments.

Conditions

  • Arginase I Deficiency
  • Hyperargininemia

Interventions

  • PegzilarginaseDrug

    Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated

  • PlaceboDrug

    Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Plasma Arginine Concentration After 24 Weeks of TreatmentTime frame: Baseline through Week 24

Locations

32 sites in 7 countries. Site status is shown where the registry gives one.

  • Harvey Pediatrics

    Rogers, Arkansas

  • Children's Hospital of Orange County

    Orange, California

  • Stanford University School of Medicine

    Stanford, California

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • University of Florida College of Medicine

    Gainesville, Florida

  • Emory University

    Atlanta, Georgia

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Cohen Children's Medical Center (Northwell Health)

    Queens, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • UT Southwestern Medical Center

    Dallas, Texas

  • University of Texas Health Science Center Medical School at Houston

    Houston, Texas

  • University of Utah Hospitals & Clinics

    Salt Lake City, Utah

  • Seattle Children's Hospital

    Seattle, Washington

  • LKH Bregenz

    Bregenz, Austria

  • Medizinische Universität Innsbruck

    Innsbruck, Austria

  • McGill University Health Center

    Montreal, Quebec, Canada

  • Hôpital Necker - Enfants Malades

    Paris, France

  • Hopital des Enfants

    Talence, France

  • Universitaetsklinikum Muenster

    Münster, North Rhine-Westphalia, Germany

  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz

    Mainz, Rhineland-Palatinate, Germany

  • Fondazione MBBM

    Monza, Italy

  • Ospedale Pediatrico Bambino Gesù

    Roma, Italy

  • Azienda Ospedaliera Città della Salute e della Scienza di Torino

    Torino, Italy

  • Birmingham Children's Hospital

    Birmingham, United Kingdom

  • University Hospital of Wales

    Cardiff, United Kingdom

  • Great Ormond Street Hospital for Children

    London, United Kingdom

  • Willink Biochemical Genetics Unit

    Manchester, United Kingdom

  • Salford Royal

    Salford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.